A neutral CB1 blocker reduced cocaine-seeking behavior in animals without the side effects of rimonabant
The neutral CB1 receptor antagonist PIMSR reduced cocaine self-administration, motivation to seek cocaine, and cue-triggered relapse in rodents through dopamine-dependent mechanisms, without being rewarding or aversive itself.
Quick Facts
What This Study Found
PIMSR dose-dependently inhibited cocaine self-administration, shifted the dose-response curve downward, decreased motivation to seek cocaine, and reduced cue-induced reinstatement. PIMSR was neither rewarding nor aversive. It attenuated cocaine-enhanced brain reward stimulation and the effects of THC and a CB1 agonist, confirming CB1 receptor involvement.
Key Numbers
PIMSR inhibited cocaine self-administration under FR5 (not FR1), reduced progressive-ratio breakpoints, and attenuated cue-induced reinstatement. Effects confirmed through CB1 knockout mice and receptor antagonism.
How They Did This
Multiple preclinical behavioral assays in rats and transgenic mice: cocaine self-administration (FR1, FR5, progressive ratio), place conditioning, intracranial self-stimulation (electrical and optogenetic), and receptor antagonist studies.
Why This Research Matters
Rimonabant, a previous CB1 antagonist, failed in clinical trials due to severe psychiatric side effects (it was an inverse agonist). PIMSR, as a neutral antagonist, may avoid these issues while still treating cocaine addiction.
The Bigger Picture
The distinction between neutral antagonists (which block the receptor without changing baseline activity) and inverse agonists (which reduce baseline activity) may be critical for developing CB1-targeting medications without the psychiatric side effects that sank rimonabant.
What This Study Doesn't Tell Us
Preclinical study only. PIMSR also inhibited sucrose self-administration, suggesting potential effects on natural reward. Human pharmacokinetics and safety are unknown.
Questions This Raises
- ?Would PIMSR's effect on natural reward (sucrose) cause appetite or motivation problems in humans?
- ?Can neutral CB1 antagonism treat other substance use disorders?
Trust & Context
- Key Stat:
- Reduced cocaine seeking without being rewarding or aversive itself
- Evidence Grade:
- Comprehensive preclinical characterization with mechanism confirmation, but no human data available.
- Study Age:
- Published in 2022.
- Original Title:
- Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research.
- Published In:
- Translational psychiatry, 12(1), 286 (2022)
- Authors:
- Galaj, Ewa(6), Hempel, Briana, Moore, Allamar, Klein, Benjamin, Bi, Guo-Hua, Gardner, Eliot L, Seltzman, Herbert H, Xi, Zheng-Xiong
- Database ID:
- RTHC-03858
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How is PIMSR different from rimonabant?
Rimonabant was an inverse agonist that reduced baseline CB1 receptor activity, causing depression and suicidality. PIMSR is a neutral antagonist that only blocks the receptor when activated, which may avoid those psychiatric side effects.
Did it completely stop cocaine use in animals?
It reduced cocaine self-administration, lowered motivation to seek cocaine, and decreased cue-triggered relapse, but did not completely eliminate cocaine-seeking behavior.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-03858APA
Galaj, Ewa; Hempel, Briana; Moore, Allamar; Klein, Benjamin; Bi, Guo-Hua; Gardner, Eliot L; Seltzman, Herbert H; Xi, Zheng-Xiong. (2022). Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research.. Translational psychiatry, 12(1), 286. https://doi.org/10.1038/s41398-022-02059-w
MLA
Galaj, Ewa, et al. "Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research.." Translational psychiatry, 2022. https://doi.org/10.1038/s41398-022-02059-w
RethinkTHC
RethinkTHC Research Database. "Therapeutic potential of PIMSR, a novel CB1 receptor neutral..." RTHC-03858. Retrieved from https://rethinkthc.com/research/galaj-2022-therapeutic-potential-of-pimsr
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.